Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06057402 · ClinicalTrials.gov registry record · Phase 4

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

A Phase 4 study of Multiple Myeloma, sponsored by Pfizer.

Recruiting
Registry status
Phase 4
Development phase
80
Enrollment target
20
Study locations

NCT06057402 is a Phase 4 study of Multiple Myeloma that is actively recruiting participants, run by Pfizer. The registered enrollment target is 80 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06057402, a Phase 4 study of Multiple Myeloma, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 4
Development phase
80 participants
Enrollment target
20
Study locations

Study Summary

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Elranatamab

Study Locations (20)

Colorado

  • UCHealth Poudre Valley Hospital - Fort Collins
  • UCHealth Harmony - Fort Collins
  • UCHealth Greeley Hospital - Greeley
  • Longs Peak Hospital - Longmont
  • UCHealth Longs Peak Medical Center - Longmont
  • UCHealth - Medical Center of the Rockies - Loveland

Florida

  • Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center - Coral Gables
  • University of Miami Hospital and Clinics Deerfield Beach - Deerfield Beach
  • Sylvester Comprehensive Cancer Center - Miami
  • University of Miami Hospital and Clinics - Griffin Cancer Research Building - Miami
  • University of Miami Hospital and Clinics - Miami

Victoria

  • Epworth Freemasons - Melbourne
  • Epworth Hospital - Richmond
  • Slade Pharmacy - Richmond

Michigan

  • University of Michigan - Ann Arbor
  • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) - Detroit

Alberta

  • Arthur J.E. Child Comprehensive Cancer Centre - Calgary
  • Cross Cancer Institute - Edmonton

Texas

  • St. David's South Austin Medical Center - Austin

Quebec

  • McGill University Health Centre - Montreal

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-10-03
Est. Completion 2032-02-22
Phase Phase 4

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06057402

The ClinicalTrials.gov registry entry for NCT06057402 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Elranatamab is the first listed.

NCT06057402 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Colorado, Florida, Victoria.

Frequently Asked Questions

What is clinical trial NCT06057402 about?

NCT06057402 is a clinical study titled "Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)". This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

What is the current status of trial NCT06057402?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2023-10-03. Estimated completion is 2032-02-22.

What conditions does trial NCT06057402 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT06057402?

The interventions under investigation include: Elranatamab (DRUG).

Who is sponsoring clinical trial NCT06057402?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06057402 being conducted?

This trial has 20 study locations across Colorado, Florida, Michigan, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.